晚期气动压缩装置治疗下肢淋巴水肿的生活质量变化评估
本研究为退伍军人事务医疗系统内开展的多中心单臂观察性临床试验,评估Flexitouch晚期气动压缩装置治疗下肢淋巴水肿的效果。共178例患者入组,报告前74例完成52周治疗的中期数据。结果显示52周时淋巴水肿生活质量评分和SF-36躯体成分显著改善,肢体周径在12周显著下降并维持稳定,蜂窝织炎发作、淋巴水肿相关门诊就诊、急诊就诊和住院均显著减少。
要点
- APCD治疗12周时患肢周径显著下降,并维持至52周。
- 52周时淋巴水肿生活质量评分和SF-36躯体成分显著改善。
- APCD治疗与蜂窝织炎发作及淋巴水肿相关医疗资源使用显著减少相关。
核心结论
- Flexitouch APCD治疗下肢淋巴水肿可在12周内实现肢体周径初步显著下降,并在≤1年内持续稳定改善健康相关生活质量。
- 生活质量改善可能反映蜂窝织炎发作减少及淋巴水肿相关门诊、急诊就诊和住院减少。
研究设计与样本
- 研究为上市后、多中心、单臂、观察性临床试验,在退伍军人事务医疗系统内开展。
- 纳入2016年2月至2019年3月期间诊断为单侧或双侧下肢原发性或继发性水肿并接受Flexitouch APCD治疗的患者。
- 共前瞻性入组178例下肢淋巴水肿患者,本研究报告前74例完成52周APCD治疗的中期数据。
- 患者在基线及入组后12、24、52周接受肢体周径、生活质量评估(SF-36和淋巴水肿生活质量)、装置依从性、蜂窝织炎发作及淋巴水肿相关医疗使用评估。
- 主要终点为基线 vs 12周生活质量、52周非计划淋巴水肿相关门诊就诊和住院;次要终点包括52周 vs 基线肢体周径和生活质量变化。
主要发现
- 队列以男性为主(94.6%),平均年龄67岁,中位体重指数32 kg/m2,最常见为静脉淋巴水肿(71.6%),多数为双下肢受累(91.9%)。
- 12周时生活质量无显著差异。
- 52周时淋巴水肿生活质量评分较基线显著改善(6.3 vs 7.4;P < .0001)。
- 52周时SF-36躯体成分较基线显著改善(38.6 vs 40.8;P = .035),精神成分有改善趋势但未达显著(49.9 vs 51.3;P = .549)。
- 12周时最受累下肢周径较基线显著下降(28.5 cm vs 27.7 cm;P = .0005),并在研究期间维持稳定。
临床怎么用
- 对于下肢淋巴水肿患者,可考虑使用Flexitouch APCD进行家庭治疗以改善肢体周径和生活质量。
- APCD治疗可能有助于减少蜂窝织炎发作及淋巴水肿相关门诊、急诊和住院资源使用。
- 疗效评估可关注12周肢体周径变化及52周生活质量改善。
局限性
- 本研究为单臂观察性试验,无对照组。
- 本报告仅为前74例完成52周治疗的中期数据,样本量有限。
- 队列以男性退伍军人为主,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Lymphedema is associated with significant morbidity and healthcare resource usage. Conventional therapy efficacy has been limited, with poor surgical salvage options. Preliminary studies have demonstrated that the use of advanced pneumatic compression devices (APCDs) improves clinical outcomes. However, limited evidence regarding their role in healthcare cost mitigation or health-related quality of life (QOL) is available. METHODS: The present postmarket, multicenter, single-arm, observational clinical trial conducted in the Veterans Affairs Healthcare System evaluated patients with a diagnosis of primary or secondary edema of unilateral or bilateral lower extremities treated with the Flexitouch APCD (Tactile Medical, Minneapolis, Minn) from February 2016 to March 2019. The patients were assessed at baseline and 12, 24, and 52 weeks from enrollment by limb circumference, QOL assessments (short form-36 and Lymphedema Quality of Life), device compliance, cellulitis episodes, and lymphedema-related healthcare use since the previous visit. The primary endpoints of interest were the QOL at baseline compared with at 12 weeks, unscheduled lymphedema-related clinic visits, and hospital admissions at 52 weeks. The secondary endpoints included the change in limb girth and QOL at 52 weeks compared with baseline. RESULTS: A total of 178 patients with lower extremity lymphedema were prospectively enrolled. The present study reports the interim data for the first 74 subjects to complete 52 weeks of APCD treatment. The cohort was predominately male (94.6%), elderly (mean age, 67 years), obese (median body mass index, 32 kg/m2), and most commonly enrolled for the treatment of phlebolymphedema (71.6%) with largely bilateral lower extremity involvement (91.9%). No significant difference was seen in QOL at 12 weeks. However, at 52 weeks, the Lymphedema Quality of Life scores had significantly improved from baseline (6.3 vs 7.4; P < .0001) and the short form-36 had demonstrated significant improvement from baseline in the physical component (38.6 vs 40.8; P = .035), with an effect toward overall improvement in the mental component (49.9 vs 51.3; P = .549). The limb circumference had decreased significantly at 12 weeks compared with baseline (28.5 cm vs 27.7 cm; P = .0005) in the most affected lower extremity, and this reduction had remained stable for the study duration. APCD treatment was associated with a significant reduction in cellulitis episodes (24.3% vs 8.1%; P = .005), lymphedema-related clinic visits (2.2 vs 0.7; P = .02), urgent care visits (1.2 vs 0.3; P = .004), and hospital admissions (0.5 vs 0.1; P = .047) per patient. CONCLUSIONS: The Flexitouch APCD resulted in initial significant limb girth reduction as early as 12 weeks and a steady and sustained improvement in health-related QOL for ≤1 year. The latter was likely reflective of a decrease in cellulitis episodes and fewer associated lymphedema-related clinic and urgent care visits and hospital admissions.
引用
- Maldonado TS, Rokosh RS, Padberg F, et al. Assessment of quality of life changes in patients with lower extremity lymphedema using an advanced pneumatic compression device at home. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 33137494. doi:10.1016/j.jvsv.2020.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。